Investigation of blood mutations in elderly lymphoma patients
Chemotherapy-induced Genomic Damage in Elderly Patients With Lymphoma: Prevalence, Evolution, and Clinical Consequences
This study is testing how blood mutations affect older patients with B-cell Non-Hodgkin lymphoma during chemotherapy to see who might do better with standard treatments or newer options that have fewer side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT05245487 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate blood mutations in elderly patients diagnosed with B-cell Non-Hodgkin lymphoma who require systemic treatment. It focuses on patients aged 60 and older, examining the impact of chemotherapy on blood cell mutations and the associated risks of treatment side effects and mortality. Blood samples will be collected at various stages of treatment, and quality of life questionnaires will be administered electronically. The study seeks to identify which patients may benefit from traditional chemotherapy versus novel therapies with fewer side effects.
Who should consider this trial
Good fit: Ideal candidates are elderly patients aged 60 and older with a diagnosis of B-cell Non-Hodgkin lymphoma requiring second-line or higher systemic treatment.
Not a fit: Patients who are unable to provide written consent or are non-Danish citizens will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help tailor lymphoma treatments to minimize toxicity and improve outcomes for elderly patients.
How similar studies have performed: While studies have examined blood mutations in younger patients, this investigation into elderly populations is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of r/r B-cell Non-Hodgkin lymphoma * In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma * 60 years of age or older (no age maximum) Exclusion Criteria: * Unable to give written consent * Non-Danish citizens
Where this trial is running
Copenhagen
- Dept. of Hematology, Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Simon Husby, MD PhD — Rigshospitalet, Denmark
- Study coordinator: Simon Husby, MD PhD
- Email: simon.husby.01@regionh.dkZZZZZZ
- Phone: +45 3545 6060
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.